Abstract： Objectives To observe the curative cffcct and safety of sunitinib in the treatment of advanced renal cell carcinoma.Methods Sixteen patients with advanced renal cell carcinoma were enrolled from September 2009 to December 2011,10 male and 6 female patients,median age was 57years( range from 38 to 74 years).Fourteen patients had prior nephrectomy,and two patients were treated with cytokines previously.15 cases of clear-cell RCC,5 cases of papillary RCC.Thirteen patients were given sunitinib at a dosage of either 50mg daily(4weeks on/2weeks off),three patients were given 37.5mg daily continuously.The treatment lasted from 6 to 27 months.Results Clinical efficacy could be evaluated in 16 patients.Of these,1 achieved complete response ( 6.3％ ),4 achieved partial response(25.0％ ),9 were stable (56.2％) and 2 experienced disease progression ( 12.5％ ),the ORR was 31.3 ％ with the disease control rate of 87.5％,However,the median PFS and OS were not yet available due to the short term follow up.During the treatment,the most common adverse events experienced by patients were hand -foot syndrome 3/16( 18.8％ ),changes in hair color 5/16(31.3％ ),mucositis 6/16 (37.5％),alopecie 2/16 ( 12.5％),diarrhea3/16( 18.8％ ) and adverse reaction of Hematopoietic System 9/16 (56.3％).Conclusions Sunitinib has a prominent effect in advanced renal cell carcinoma in a Chinese population with mostly mild to moderate adverse reactions.More attention should be paid to adverse reaction of Hematopoietic System.